Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline.

J Clin Endocrinol Metab. 2011 Jun 6.
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM.

Boston University School of Medicine (M.F.H.), Boston, Massachusetts 02118; University of Wisconsin (N.C.B.), Madison, Wisconsin 53706; University Hospital Zurich (H.A.B.-F.), CH-8091 Zurich, Switzerland; Children's Hospital Boston (C.M.G.), Boston, Massachusetts 02115; University of Calgary Faculty of Medicine (D.A.H.), Calgary, Alberta, Canada T2N 1N4; Creighton University (R.P.H.), Omaha, Nebraska 68178; Mayo Clinic (M.H.M.), Rochester, Minnesota 55905; and Purdue University (C.M.W.), West Lafayette, Indiana 47907.

Objective: The objective was to provide guidelines to clinicians for the evaluation, treatment, and prevention of vitamin D deficiency with an emphasis on the care of patients who are at risk for deficiency. Participants: The Task Force was composed of a Chair, six additional experts, and a methodologist. The Task Force received no corporate funding or remuneration. Consensus Process: Consensus was guided by systematic reviews of evidence and discussions during several conference calls and e-mail communications. The draft prepared by the Task Force was reviewed successively by The Endocrine Society's Clinical Guidelines Subcommittee, Clinical Affairs Core Committee, and cosponsoring associations, and it was posted on The Endocrine Society web site for member review. At each stage of review, the Task Force received written comments and incorporated needed changes.

Conclusions: Considering that vitamin D deficiency is very common in all age groups and that few foods contain vitamin D, the Task Force recommended supplementation at suggested daily intake and tolerable upper limit levels, depending on age and clinical circumstances. The Task Force also suggested the measurement of serum 25-hydroxyvitamin D level by a reliable assay as the initial diagnostic test in patients at risk for deficiency. Treatment with either vitamin D(2) or vitamin D(3) was recommended for deficient patients. At the present time, there is not sufficient evidence to recommend screening individuals who are not at risk for deficiency or to prescribe vitamin D to attain the noncalcemic benefit for cardiovascular protection.

PMID: 21646368
 Download the PDF from Vitamin D Life

-- - - - - - - - -
Defines Vitamin D insufficiency as 20-29 nanograms/ml
- continue with Deficiency as < 20 nanograms/ml - as voted on by Institute of Medicine Nov 2010

Table from Hormone society PDF attached to bottom of this page

Comparison of Institute of Medicine Recommendations and Endocrine Society Suggestions

Summary of Society Suggestions - by Dr. Bromley

TABLE 2. Candidates for screening

Rickets
Osteomalacia
Osteoporosis
Chronic kidney disease
Hepatic failure
Malabsorption syndromes
  Cystic fibrosis
  Inflammatory bowel disease
  Crohn's disease
  Bariatric surgery
  Radiation enteritis
  Hyperparathyroidism
Medications
  Antiseizure medications
  Glucocorticoids
  AIDS medications
  Antifungals, e.g. ketoconazole
  Cholestyramine
African-American and Hispanic children and adults
Pregnant and lactating women
Older adults with history of falls
Older adults with history of nontraumatic fractures
Obese children and adults (BMI > 30 kg/m2)
Granuloma-forming disorders
  Sarcoidosis
  Tuberculosis
  Histoplasmosis
  Coccidiomycosis
  Berylliosis
  Some lymphomas

Note: Vitamin D Life disagrees with one point: D2 is not nearly as beneficial as D3 - see links below

Dr. Hollick, a powerful member of the Endocrine Society, is one of the few doctors around the world who still believes that D2 is as good as D3

- - - - - - -

See also Vitamin D Life

• Vitamin D Recommendations
• All items in category D3 vs D2 100 items
• Endocrine Society Guideline should be raised to 2 ng per 100 IU of vitamin D – March 2013